ATE538775T1 - Ketorolac-tromethamin-zusammensetzungen zur behandlung oder prävention von schmerz - Google Patents

Ketorolac-tromethamin-zusammensetzungen zur behandlung oder prävention von schmerz

Info

Publication number
ATE538775T1
ATE538775T1 AT09716497T AT09716497T ATE538775T1 AT E538775 T1 ATE538775 T1 AT E538775T1 AT 09716497 T AT09716497 T AT 09716497T AT 09716497 T AT09716497 T AT 09716497T AT E538775 T1 ATE538775 T1 AT E538775T1
Authority
AT
Austria
Prior art keywords
ketorolac
tromethamin
pain
prevention
compositions
Prior art date
Application number
AT09716497T
Other languages
English (en)
Inventor
Eldon Quinn Farnes
Mayssa Attar
Rhett M Schiffman
Chin-Ming Chang
Richard S Graham
Devin F Welty
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40852460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE538775(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE538775T1 publication Critical patent/ATE538775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT09716497T 2008-03-03 2009-03-03 Ketorolac-tromethamin-zusammensetzungen zur behandlung oder prävention von schmerz ATE538775T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6792508P 2008-03-03 2008-03-03
US9609608P 2008-09-11 2008-09-11
US11191908P 2008-11-06 2008-11-06
US12/396,131 US7842714B2 (en) 2008-03-03 2009-03-02 Ketorolac tromethamine compositions for treating ocular pain
PCT/US2009/035787 WO2009111418A2 (en) 2008-03-03 2009-03-03 Ketorolac tromethamine compositions for treating or preventing ocular pain

Publications (1)

Publication Number Publication Date
ATE538775T1 true ATE538775T1 (de) 2012-01-15

Family

ID=40852460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09716497T ATE538775T1 (de) 2008-03-03 2009-03-03 Ketorolac-tromethamin-zusammensetzungen zur behandlung oder prävention von schmerz

Country Status (20)

Country Link
US (10) US7842714B2 (de)
EP (2) EP2446878B1 (de)
JP (1) JP5705552B2 (de)
KR (1) KR101560429B1 (de)
CN (1) CN102014869A (de)
AT (1) ATE538775T1 (de)
AU (1) AU2009222016B2 (de)
BR (1) BRPI0909100B1 (de)
CA (1) CA2717520C (de)
CO (1) CO6321226A2 (de)
DK (2) DK2257275T3 (de)
ES (2) ES2382509T3 (de)
HU (1) HUE027102T2 (de)
IL (1) IL207925A (de)
MX (1) MX2010009763A (de)
MY (1) MY150250A (de)
NZ (2) NZ602445A (de)
PL (2) PL2446878T3 (de)
WO (1) WO2009111418A2 (de)
ZA (1) ZA201006372B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654002B2 (de) * 2003-08-07 2014-01-29 Allergan, Inc. Zusammensetzungen zur abgabe von therapeutika in die augen
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
AU2011237646A1 (en) * 2010-04-09 2012-11-08 Allergan, Inc. Ketorolac compositions for corneal wound healing
WO2013085769A1 (en) * 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
DE102013006596A1 (de) * 2013-04-17 2014-10-23 Jaime Guardiola Verfahren zum Herstellen einer sterilen intraokularen Spül-Lösung und Spül-Lösung
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150335704A1 (en) 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CA3033507A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
US20200170998A1 (en) * 2018-11-29 2020-06-04 Cellula Llc Umbilical cord blood serum and umbilical cord blood plasma preparation in combination with a nonsteroidal anti-inflammatory drug and freeze-drying the composition
US20220411482A1 (en) 2019-11-15 2022-12-29 Silk Technologies, Ltd. Stable formulations of silk-derived protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE1544943A1 (de) * 1964-02-12 1969-07-31 Goodrich Co B F Waermehaertbare Vinylplastisole
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4021416A (en) * 1975-05-05 1977-05-03 Polaroid Corporation Thiol polymers
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US6255299B1 (en) 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4861514A (en) 1988-06-08 1989-08-29 The Drackett Company Compositions containing chlorine dioxide and their preparation
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
US5045121A (en) * 1989-06-21 1991-09-03 Gte Products Corporation Method for removing carbon from cemented tungsten carbide articles
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5648074A (en) 1993-05-25 1997-07-15 Allergan Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation
AU688380B2 (en) 1993-10-13 1998-03-12 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
CA2365767A1 (en) 1999-03-15 2000-09-21 Trustees Of Boston University Angiogenesis inhibition
JP2002541682A (ja) * 1999-04-08 2002-12-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ パンチスルーダイオード及び同ダイオードを製造する方法
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
US7141607B1 (en) * 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
EP1365811A2 (de) * 2000-07-14 2003-12-03 Allergan, Inc. Zusammensetzungen enthaltend alpha-2-adrenergische agonisten
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP1654002B2 (de) * 2003-08-07 2014-01-29 Allergan, Inc. Zusammensetzungen zur abgabe von therapeutika in die augen
WO2005101982A2 (en) 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
KR20070091682A (ko) 2004-12-23 2007-09-11 록스로 파마 인코퍼레이티드 케토롤락의 비내 투여용 치료 조성물
US20070299124A1 (en) * 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20080039398A1 (en) * 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
CN101754748A (zh) * 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7820661B2 (en) * 2008-04-24 2010-10-26 Allergan, Inc. Substituted gamma lactams as therapeutics agents
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Also Published As

Publication number Publication date
US20090326034A1 (en) 2009-12-31
HK1149212A1 (en) 2011-09-30
CN102014869A (zh) 2011-04-13
JP2011513416A (ja) 2011-04-28
EP2257275A2 (de) 2010-12-08
DK2257275T3 (da) 2012-04-02
WO2009111418A3 (en) 2010-04-01
EP2446878A1 (de) 2012-05-02
PL2446878T3 (pl) 2016-06-30
EP2446878B1 (de) 2015-12-30
CA2717520A1 (en) 2009-09-11
US20250281432A1 (en) 2025-09-11
IL207925A0 (en) 2010-12-30
US20110160271A1 (en) 2011-06-30
AU2009222016A1 (en) 2009-09-11
US20200197336A1 (en) 2020-06-25
BRPI0909100B1 (pt) 2019-01-15
NZ602445A (en) 2014-06-27
WO2009111418A2 (en) 2009-09-11
US20230181497A1 (en) 2023-06-15
ES2566162T3 (es) 2016-04-11
US20110275688A1 (en) 2011-11-10
US20240197657A1 (en) 2024-06-20
MX2010009763A (es) 2010-12-07
CA2717520C (en) 2012-05-01
AU2009222016B2 (en) 2014-09-04
KR101560429B1 (ko) 2015-10-15
JP5705552B2 (ja) 2015-04-22
US7842714B2 (en) 2010-11-30
ES2382509T3 (es) 2012-06-08
US20120196913A1 (en) 2012-08-02
DK2446878T3 (en) 2016-04-04
HUE027102T2 (en) 2016-08-29
ZA201006372B (en) 2011-05-25
BRPI0909100A2 (pt) 2015-08-11
KR20100130989A (ko) 2010-12-14
IL207925A (en) 2015-03-31
CO6321226A2 (es) 2011-09-20
US20120196914A1 (en) 2012-08-02
EP2257275B1 (de) 2011-12-28
MY150250A (en) 2013-12-31
US20110046198A1 (en) 2011-02-24
PL2257275T3 (pl) 2012-05-31
NZ588367A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PL2257275T3 (pl) Kompozycje trometaminy ketorolaku do leczenia lub zapobiegania bólu ocznego
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
IN2012DN00624A (de)
EP2415763A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von glaukom
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EP2278999C0 (de) Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201170349A1 (ru) Модуляторы mif
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201390707A1 (ru) Способ лечения контраст-индуцированной нефропатии
EP2470553C0 (de) Polyhydroylierte gallensäure zur behandlung von gallenerkrankungen
BRPI0917552B8 (pt) kit para o tratamento de onicomicose
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EP2415476A4 (de) Zusammensetzung zur vorbeugung und/oder behandlung von hautkrankheiten
EA200802364A1 (ru) Композиция для ухода за кожей и ее применение
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
EA201591180A1 (ru) Составы ингибитора lfa-1
EP4582141A3 (de) Orale zusammensetzung zur behandlung von gastroösophagealem reflux und laryngopharyngealem reflux